Victrex plc (LON:VCT) has been given a consensus rating of “Hold” by the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is GBX 2,526.11 ($33.01).
VCT has been the subject of several research reports. Liberum Capital reaffirmed a “buy” rating and set a GBX 2,825 ($36.91) price target on shares of Victrex in a research report on Wednesday, July 25th. Barclays reaffirmed an “underweight” rating and set a GBX 2,380 ($31.10) price target (up previously from GBX 2,300 ($30.05)) on shares of Victrex in a research report on Tuesday, July 24th. Citigroup reaffirmed a “neutral” rating on shares of Victrex in a research report on Tuesday, July 17th. UBS Group reaffirmed a “buy” rating and set a GBX 3,600 ($47.04) price target (up previously from GBX 3,300 ($43.12)) on shares of Victrex in a research report on Thursday, October 4th. Finally, Morgan Stanley upped their price target on shares of Victrex from GBX 1,600 ($20.91) to GBX 2,980 ($38.94) and gave the company an “equal weight” rating in a research report on Monday, July 16th.
Shares of LON VCT traded down GBX 126 ($1.65) during midday trading on Wednesday, hitting GBX 2,618 ($34.21). 981,245 shares of the company’s stock traded hands, compared to its average volume of 274,177. Victrex has a 1 year low of GBX 1,826 ($23.86) and a 1 year high of GBX 2,772 ($36.22).
In other news, insider Jakob Sigurdsson bought 3,250 shares of Victrex stock in a transaction that occurred on Wednesday, July 25th. The stock was bought at an average cost of GBX 3,072 ($40.14) per share, with a total value of £99,840 ($130,458.64). Insiders purchased a total of 3,262 shares of company stock valued at $10,021,700 over the last three months.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Read More: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.